TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04539353

Intervention type: OTHER
Intervention: Heart Rate Variability
Description: Heart Rate Variability will be measured with a Polar device.

Intervention type: OTHER
Intervention: Pain intensity
Description: Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
Study: NCT00737243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, 1-3 hour IV infusion Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 IV Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV infusion Day 1
Study: NCT01729819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin orally disintegrating tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo orally disintegrating tablets
Study: NCT01756417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
Study: NCT04096144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents
Description: Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents
Description: Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
Study: NCT01654705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg Delayed release tablets (Test Product)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Protonix® Delayed Release 40 mg tablets (Reference product)
Study: NCT02535624

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PACKING
Description: By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ANGIO
Description: Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
Study: NCT01037530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5 mg/day for 2 weeks then 10 mg/day for 22 weeks
Study: NCT03002844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: EGFR-TKI (gefitinib 250mg per day)
Study: NCT02798887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation
Description: Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation
Description: Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
Study: NCT01217892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 2.5 mg tablet, taken orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 5 mg tablet taken orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 10 mg tablet taken orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: \>/= 1500 mg total daily dose, tablets taken orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: \>/= 1500 mg total daily dose, tablets taken orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: \>/= 1500 mg total daily dose, tablets taken orally, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: \>/= 1500 mg total daily dose, tablets taken orally, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03359161

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sc2Wear Furosemide Infusor
Description: Subcutaneous furosemide for the treatment of fluid overload
Study: NCT04168125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilapia skin
Description: Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
Study: NCT03002844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: EGFR-TKI (gefitinib 250mg per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI and Chemotherapy
Description: pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
Study: NCT01976754

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
Study: NCT03465007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
Study: NCT03780816

Intervention type: OTHER
Intervention: Observation of provider-patient interactions and interviews
Description: Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.

Intervention type: OTHER
Intervention: Observation of provider-patient interactions and interviews
Description: Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.

Intervention type: OTHER
Intervention: Observation of provider-patient interactions and interviews
Description: Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.

Intervention type: OTHER
Intervention: Observation of provider-patient interactions and interviews
Description: Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
Study: NCT05264467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin on colorectal anastomosis
Description: Platelet rich fibrin on colorectal anastomosis
Study: NCT02039180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293 oral solution
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293 tablet formulation A
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
Study: NCT04622826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immune plasma
Description: immune covid 19 plasma infusion
Study: NCT04168125

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Wound Dressing
Description: Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
Study: NCT04009070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture Pres Needle: 0.22x1.5 mm needle
Description: Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
Study: NCT00580437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dobutamine Stress Echocardiogram
Description: stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
Study: NCT02039180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293 tablet formulation B
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
Study: NCT01627067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
Study: NCT05631015

Intervention type: OTHER
Intervention: AI recongnize disease and generate recommendations
Description: According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
Study: NCT00339183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
Study: NCT01226420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
Study: NCT03978819

Intervention type: DEVICE
Intervention: ANI
Description: ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI\>80 + Remifentanil \>6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis.
Study: NCT03407924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Description: Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
Study: NCT04048304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duration of standard antibiotic therapy
Description: antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duration of standard antibiotic therapy
Description: antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
Study: NCT01145456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04345614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auxora
Description: Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
Study: NCT01145456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02135458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional care
Study: NCT03771846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, oxaliplatin , fluorouracil, and leucovorin
Description: administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study: NCT04345614

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
Study: NCT03771846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and oxaliplatin
Description: administration of gemcitabine and oxaliplatin via vein
Study: NCT02622659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiaoer Jiebiao Oral Liquid
Description: 1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day
Study: NCT03226171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-adjusted SK-1403
Description: SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
Study: NCT04409444

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Cancer Screening
Description: The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Cancer Screening
Description: The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
Study: NCT02323386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary Total Knee Arthroplasty (ATTUNE Knee System)
Description: The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected.
Study: NCT04028258

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mixture of fibers + Placebo
Description: Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo + Mixture of fibers
Description: Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
Study: NCT02648360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
Study: NCT02663193

Intervention type: OTHER
Intervention: No Intervention
Description: Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.

Intervention type: OTHER
Intervention: No Intervention
Description: Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
Study: NCT03135860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide 30mcg/kg IBW/hr
Description: Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
Study: NCT00737243

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 15 mg/kg IV infusion Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg PO

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150 mg PO

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment determined by physician
Description: Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
Study: NCT00677131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading the package insert of the drug
Description: package insert of the drug
Study: NCT03992495

Intervention type: OTHER
Intervention: Exercise
Description: All participants will be exposed to aerobic/strengthening exercises

Intervention type: OTHER
Intervention: Exercise
Description: All participants will be exposed to aerobic/strengthening exercises
Study: NCT00677131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading the education information provided by the Pharmacy of NTUH
Description: education information
Study: NCT01702298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/simvastatin 40 mg FDC
Description: Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
Study: NCT02504619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CordIn
Description: CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
Study: NCT01809964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT02824367

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Completion of scales evaluation
Description: Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Completion of scales evaluation
Description: Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
Study: NCT01376141

Intervention type: DRUG
Intervention: Sumatriptan
Study: NCT03093792

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Heart Association plus exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Curves Complete - I plus exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Curves Complete - II plus exercise
Study: NCT02192034

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Navigation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Study: NCT02299635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 10 mg, twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 50 mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 100 mg, twice a day
Study: NCT04147416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486 0.1-0.2 /0.3 mg / kg group
Description: Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 0.5-1.0/1.5 mg/kg group
Description: Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
Study: NCT03278028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution
Description: A-101 Topical Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle Solution
Description: A-101 Vehicle Solution